ClinicalTrials.gg
RecruitingNCT07897370Updated Oct 27, 2026

Cardiac Arrest - Ultrasound Detection of Occult Perfusion

An observational study in Cardiac Arrest, Out-Of-Hospital and Hypotension, sponsored by University of Massachusetts, Worcester. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University of Massachusetts, Worcester · Observational

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 27, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,400
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to describe the population of patients presenting after out of hospital cardiac arrest with occult perfusion, defined as a patient without a palpable pulse but with some evidence of pulsatile arterial flow. The main questions it aims to answer are:

  • To measure the prevalence of patients of patients presenting to the emergency department after out of hospital cardiac arrest with occult perfusion
  • To measure the association between occult perfusion and survival
  • Compare survival between patients with occult perfusion that were treated as pulseless by ACLS interventions vs those treated as hypotensive

Researchers will describe the percentage of out-of-hospital cardiac arrest presenting to the emergency department without a pulse but with occult perfusion. Researchers will also compare survival endpoints (ROSC, Survival to hospital Admission, and Survival to Hospital Discharge) in pulseless patients with occult perfusion treated with ACLS interventions only and pulseless patients with occult perfusion treated as if they had pulsatile arterial flow.

Participants will undergo resuscitation based on decisions by the clinical team who incorporate echo and/or vascular ultrasound during the first three rounds of CPR. The resuscitation will continue until the patient demonstrates return of spontaneous circulation or until the clinical team halts resuscitative efforts due to futility.

Read the detailed description

This is a multi-center, prospective, observational trial involving sites across the United States and Canada. Patients having suffered an out of hospital cardiac arrest will be enrolled through the emergency department either presenting in cardiac arrest with ongoing CPR or having been resuscitated en-route but re-arresting shortly after arriving in the emergency department.

Patients will undergo any echocardiography or vascular ultrasound during the resuscitation at the discretion of the clinical team and based on institutional protocols. The clinical team will be unblinded to any aspect of the resuscitation, including the echo or vascular ultrasound images. Clinical interventions during the pause in CPR will be classified as ACLS interventions for cardiac arrest or non-ACLS interventions for occult perfusion. ACLS interventions include interventions for cardiac arrest such as bolus epinephrin or CPR. Non-ACLS interventions for occult perfusion include interventions for patients with profound hypotension such as continuous adrenergic agents or halting CPR to check a blood pressure.

Patients will be determined to have demonstrated occult perfusion based on blinded review of the patient data, ultrasound images, and vascular images.

Adjudicated Echo Image Review - Recorded cardiac images blinded to all patient and sonographer information will be reviewed by research staff to identify if a) cardiac activity is present and b) organized cardiac activity is present. Cardiac output will be measured as fractional shortening of the left ventricular chamber. Images will be reviewed separately by expert reviewers blinded to all patient information with adjudication by a third when there is disagreement.

Adjudicated Vascular Image Review - Recorded vascular images blinded to all patient and sonographer information will be reviewed by research staff to identify if arterial pulsations are visible. Measurements on the B-mode imaging will include a) artery diameter (superficial to deep) b) artery diameter (side to side) c) depth of artery from skin surface and d) area of the artery cross section at peak systole and peak diastole. The pulsatile index will be calculated as the ratio of the maximal artery diameter during a single pulsation (superficial to deep) to the minimal artery diameter during a single pulsation(superficial to deep). Images will be reviewed separately by expert reviewers blinded to all patient information with adjudication by a third when there is disagreement.

Patients will be classified as demonstrating occult perfusion with the following findings:

  • organized cardiac activity by echo determined to be sufficient to produce an arterial pulse
  • pulsatile arterial flow visible on vascular ultrasound determined to be significant

The study has a number of pre-determined study end points that are observational and associative in nature. They include the following:

  • Assessment of ECG interpretation accuracy based on comparison of expert review interpretation of ECG and initial clinical interpretation
  • Exploratory assessment of number of patients treated as cardiac arrest with bolus EPI and CPR that are determined to be occult perfusion better treated with non-ACLS intervention such as stopping CPR and starting continuous adrenergic agents. The methodology for this is not described in full but will involve a modified Delphi of patient data to determine appropriate categorization.
02

Conditions studied

  • Cardiac Arrest, Out-Of-Hospital
  • Hypotension

Keywords

  • Echocardiography
  • Vascular Ultrasound
  • Cardiac Arrest
  • Out of hospital cardiac arrest
  • Cardiopulmonary Resuscitation
03

In context

Out-of-Hospital Cardiac Arrest

314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.

This study's planned enrollment of 1,400 is above the median of 300 across 128 observational studies indexed under Out-of-Hospital Cardiac Arrest.

Browse Out-of-Hospital Cardiac Arrest studies →

Lead sponsor

University of Massachusetts, Worcester is the lead sponsor of 291 studies on the registry; 51 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients presenting to the emergency department following atraumatic cardiac arrest with ongoing resuscitation will be considered for enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients presenting following out-of-hospital atraumatic cardiac arrest

Exclusion criteria

Exclusion Criteria:

  • Resuscitation ended due to end-of-life decisions
  • Documented allergy to ultrasound gel
  • Technical malfunction of ultrasound machine during imaging that prevents use
  • Ultrasound machine unable to record images
  • Cardiac Ultrasound not performed during first, second or third pause in CPR AND vascular Ultrasound not performed during first, second or third pause in CPR
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Occult Perfusion treated as Cardiac Arrest

    Patients presenting after cardiac arrest without a palpable pulse during pauses in CPR but echo or vascular ultrasound findings consistent with pulsatile arterial flow and treated as cardiac arrest with ACLS intervention such as rapid resumption of CPR, bolus epinephrine, or defibrillation.

  • Occult Perfusion treated as Hypotension

    Patients presenting after cardiac arrest without a palpable pulse during pauses in CPR but with echo or vascular ultrasound findings consistent with pulsatile arterial flow AND treated as hypotension with non-ACLS intervention such as continuous adrenergic agents, intravenous fluid, and extend pause in CPR to verify the presence of a measurable blood pressure.

06

What researchers measure

Primary outcomes

  1. Survival Rate (to Hospital Admission)

    The percentage of patients that demonstrate survival that lasts long enough to be admitted to the hospital. Survival is defined as resumption of a sustained, perfusing cardiac activity after cardiac arrest characterized by restoring a palpable pulse, autonomous heart rhythm, and measurable blood pressure lasting long enough to be admitted to the hospital.

    Time frame: Day 1

Secondary outcomes

  1. Return of Spontaneous Circulation

    The percentage of patients that demonstrate a resumption of spontaneous coruscation (ROSC). ROSC is defined as the resumption of a sustained, perfusing cardiac activity after cardiac arrest characterized by restoring a palpable pulse, autonomous heart rhythm, and measurable blood pressure.

    Time frame: Day 1

  2. Survival to Hospital Discharge

    The percentage of patients that demonstrate survival that lasts long enough to be discharged from the hospital.

    Time frame: Up to 1 month

07

Study locations

1 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Only IPD used in the results publication will be shared

Supporting information: Study protocol, Clinical study report

Time frame: IPD sharing begins 12 months after article publication and will last for 5 years

Access criteria: Who will be able to access: Qualified researchers engaging in independent scientific research What they will be able to access: De-identified individual participant data sets, along with supporting documentation including the study protocol and the case report form. How they will be able to access it: Data is provided following the review and approval of a formal research proposal and statistical analysis plan, followed by the execution of a signed Data Sharing Agreement (DSA). Requests can be submitted via the contact email for the study PI.

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07897370
Collaborators
Vanderbilt University School of Medicine, Dartmouth-Hitchcock Medical Center, University of Washington, Truman Medical Center, Icahn School of Medicine at Mount Sinai, MaineHealth, Hennepin Healthcare, University of Florida, University of Tennessee, Chattanooga, University of Kentucky, Maimonides Medical Center, Wake Forest University Health Sciences, University of Arkansas, Christiana Care Health Services, Beth Israel Deaconess Medical Center, Kaweah Delta Health Care District, SBH Health System, Brown University, Prisma Health Richland Hospital, University of Arizona, Boston Medical Center, University of Pittsburgh, Medical College of Wisconsin, State University of New York - Upstate Medical University, Denver Health Medical Center, Case Western Reserve University, Mayo Clinic, Hartford Hospital, advocate christ medical center, Virginia Commonwealth University, Stony Brook University
Responsible party
Romolo Gaspari (Primary Investigator - REASON Network, Executive Vice Chair, Department of Emergency Medicine, UMass Chan Medical School, University of Massachusetts, Worcester) — Principal investigator
First posted
Oct 27, 2026
Start date
Oct 1, 2026
Primary completion
Mar 1, 2029 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion